Lessons from French national guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients

Thrombosis Research

Volumn 125, Issue , 2010, Pages S108-S116

  Farge, Dominique ^a   Durant, Cecile ^a   Villiers, Stéphane ^a   Long, Anne ^b   Mahr, Alfred ^c   Marty, Michel ^b   Debourdeau, Philippe ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b REIMS UNIVERSITY HOSPITAL   (France)

^c université Paris Cité   (France)

Author keywords

Cancer; Central venous catheter (CVC) related thrombosis; Clinical guidelines; Deep vein thrombosis (DVT); Pulmonary embolism (PE); Venous thromboembolism (VTE)

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

CLINICAL TRIAL; FRANCE; HUMAN; NEOPLASM; PRACTICE GUIDELINE; REVIEW; UPPER EXTREMITY DEEP VEIN THROMBOSIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; FRANCE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; UPPER EXTREMITY DEEP VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 77955479652     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(10)70027-X     Document Type: Article

References (70)

1. Heit, JA, Silverstein, MD, Mohr, DN, Petterson, TM, O'Fallon, WM, Melton, LJ 3rd, Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160:6 (2000), 809–815.
2. Spencer, FA, Lessard, D, Emery, C, Reed, G, Goldberg, RJ, Venous thromboembolism in the outpatient setting. Arch Intern Med 167:14 (2007), 1471–1475.
3. Levitan, N, Dowlati, A, Remick, SC, Tahsildar, HI, Sivinski, LD, Beyth, R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78:5 (1999), 285–291.
4. Khorana, AA, Francis, CW, Culakova, E, Kuderer, NM, Lyman, GH, Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110:10 (2007), 2339–2346.
5. Meyer, G, Marjanovic, Z, Valcke, J, Lorcerie, B, Gruel, Y, Solal-Celigny, P, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162:15 (2002), 1729–1735.
6. Lee, AY, Levine, MN, Baker, RI, Bowden, C, Kakkar, AK, Prins, M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:2 (2003), 146–153.
7. Hull, RD, Pineo, GF, Brant, RF, Mah, AF, Burke, N, Dear, R, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119:12 (2006), 1062–1072.
8. Ferretti, G, Bria, E, Giannarelli, D, Carlini, P, Felici, A, Mandala, M, et al. Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?. Chest 130:6 (2006), 1808–1816.
9. Akl, EA, Kamath, G, Kim, SY, Yosuico, V, Barba, M, Terrenato, I, et al. Oral anticoagulation may prolong survival of a subgroup of patients with cancer: a cochrane systematic review. J Exp Clin Cancer Res 26:2 (2007), 175–184.
10. Kuderer, NM, Khorana, AA, Lyman, GH, Francis, CW, A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 110:5 (2007), 1149–1161.
11. Akl, EA, Barba, M, Rohilla, S, Terrenato, I, Sperati, F, Muti, P, et al. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev(2), 2008 CD006650.
12. Akl, EA, Rohilla, S, Barba, M, Sperati, F, Terrenato, I, Muti, P, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev(1), 2008 CD006649.
13. Noble, SI, Shelley, MD, Coles, B, Williams, SM, Wilcock, A, Johnson, MJ, Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol 9:6 (2008), 577–584.
14. Louzada, ML, Majeed, H, Wells, PS, Efficacy of low-molecular-weight-heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res 123:6 (2009), 837–844.
15. Mandala, M, Falanga, A, Piccioli, A, Prandoni, P, Pogliani, EM, Labianca, R, et al. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 59:3 (2006), 194–204.
16. Venous thromboembolic disease NCCN guidelines V2.2009. 2009. http://www.nccn.org/professionals/physician_gls/PDF/vte.pdf. Access on 08.01.2010.
17. Khorana, AA, The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: strategies for improving VTE prophylaxis in hospitalized cancer patients. Oncologist 12:11 (2007), 1361–1370.
18. Lyman, GH, Khorana, AA, Falanga, A, Clarke-Pearson, D, Flowers, C, Jahanzeb, M, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:34 (2007), 5490–5505.
19. Farge, D, Bosquet, L, Kassab-Chahmi, D, Mismetti, P, Elalamy, I, Meyer, G, et al. 2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group. Crit Rev Oncol Hematol 73:1 (2010), 31–46.
20. Debourdeau, P, Kassab Chahmi, D, Le Gal, G, Kriegel, I, Desruennes, E, Douard, MC, et al. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol 20:9 (2009), 1459–1471.
21. Geerts, WH, Bergqvist, D, Pineo, GF, Heit, JA, Samama, CM, Lassen, MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:6 Suppl (2008), 381S–453S.
22. Kearon, C, Kahn, SR, Agnelli, G, Goldhaber, S, Raskob, GE, Comerota, AJ, Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:6 Suppl (2008), 454S–545S.
23. Prévention et traitement de la maladie Thromboembolique veineuse. 2009. AFSSAPS. http://www.afssaps.fr/Infos-de-securite/Recommandations-de-bonne-pratique/Prevention-et-traitement-de-la-maladie-thromboembolique-veineuse-en-medecine-recommandations-de-bonne-pratique/(language)/fre-FR. Access on01.08.2010.
24. Palumbo, A, Rajkumar, SV, Dimopoulos, MA, Richardson, PG, San Miguel, J, Barlogie, B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22:2 (2008), 414–423.
25. Cohen, AT, Tapson, VF, Bergmann, JF, Goldhaber, SZ, Kakkar, AK, Deslandes, B, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371:9610 (2008), 387–394.
26. Kucher, N, Spirk, D, Kalka, C, Mazzolai, L, Nobel, D, Banyai, M, et al. Clinical predictors of prophylaxis use prior to the onset of acute venous thromboembolism in hospitalized patients SWIss Venous ThromboEmbolism Registry (SWIVTER). J Thromb Haemost 6:12 (2008), 2082–2087.
27. Imberti, D, Agnelli, G, Ageno, W, Moia, M, Palareti, G, Pistelli, R, et al. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica 93:2 (2008), 273–278.
28. Monreal, M, Falga, C, Valdes, M, Suarez, C, Gabriel, F, Tolosa, C, et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 4:9 (2006), 1950–1956.
29. Seddighzadeh, A, Shetty, R, Goldhaber, SZ, Venous thromboembolism in patients with active cancer. Thromb Haemost 98:3 (2007), 656–661.
30. Blom, JW, Vanderschoot, JP, Oostindier, MJ, Osanto, S, van der Meer, FJ, Rosendaal, FR, Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 4:3 (2006), 529–535.
31. White, RH, Chew, H, Wun, T, Targeting patients for anticoagulant prophylaxis trials in patients with cancer: who is at highest risk?. Thromb Res 120:Suppl 2 (2007), S29–S40.
32. Otten, HM, Mathijssen, J, ten Cate, H, Soesan, M, Inghels, M, Richel, DJ, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 164:2 (2004), 190–194.
33. Weijl, NI, Rutten, MF, Zwinderman, AH, Keizer, HJ, Nooy, MA, Rosendaal, FR, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 18:10 (2000), 2169–2178.
34. Khorana, AA, Malignancy, thrombosis and Trousseau: the case for an eponym. J Thromb Haemost 1:12 (2003), 2463–2465.
35. Agnelli, G, Bolis, G, Capussotti, L, Scarpa, RM, Tonelli, F, Bonizzoni, E, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 243:1 (2006), 89–95.
36. Martino, MA, Borges, E, Williamson, E, Siegfried, S, Cantor, AB, Lancaster, J, et al. Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol 107:3 (2006), 666–671.
37. Andtbacka, RH, Babiera, G, Singletary, SE, Hunt, KK, Meric-Bernstam, F, Feig, BW, et al. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg 243:1 (2006), 96–101.
38. Verso, M, Agnelli, G, Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21:19 (2003), 3665–3675.
39. Khorana, AA, Francis, CW, Culakova, E, Kuderer, NM, Lyman, GH, Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:3 (2007), 632–634.
40. Sorensen, HT, Mellemkjaer, L, Olsen, JH, Baron, JA, Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:25 (2000), 1846–1850.
41. Chew, HK, Wun, T, Harvey, D, Zhou, H, White, RH, Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:4 (2006), 458–464.
42. Mason, DP, Quader, MA, Blackstone, EH, Rajeswaran, J, DeCamp, MM, Murthy, SC, et al. Thromboembolism after pneumonectomy for malignancy: an independent marker of poor outcome. J Thorac Cardiovasc Surg 131:3 (2006), 711–718.
43. Tetsche, MS, Norgaard, M, Pedersen, L, Lash, TL, Sorensen, HT, Prognosis of ovarian cancer subsequent to venous thromboembolism: a nationwide Danish cohort study. BMC Cancer, 6, 2006, 189.
44. Alcalay, A, Wun, T, Khatri, V, Chew, HK, Harvey, D, Zhou, H, et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 24:7 (2006), 1112–1118.
45. Prandoni, P, Lensing, AW, Piccioli, A, Bernardi, E, Simioni, P, Girolami, B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:10 (2002), 3484–3488.
46. Elting, LS, Escalante, CP, Cooksley, C, Avritscher, EB, Kurtin, D, Hamblin, L, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 164:15 (2004), 1653–1661.
47. Nalluri, SR, Chu, D, Keresztes, R, Zhu, X, Wu, S, Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:19 (2008), 2277–2285.
48. Bennett, CL, Silver, SM, Djulbegovic, B, Samaras, AT, Blau, CA, Gleason, KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:8 (2008), 914–924.
49. Mandala, M, Falanga, A, Roila, F, Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 20:Suppl 4 (2009), 182–184.
50. Wagman, LD, Baird, MF, Bennett, CL, Bockenstedt, PL, Cataland, SR, Fanikos, J, et al. Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 4:9 (2006), 838–869.
51. Mandala, M, Falanga, A, Roila, F, Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 19:Suppl 2 (2008), ii126–ii127.
52. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 12:1 (2003), 18–23.
53. Hadley, SA, Chang, M, Rogers, K, Effect of syringe size on bruising following subcutaneous heparin injection. Am J Crit Care 5:4 (1996), 271–276.
54. Sideras, K, Schaefer, PL, Okuno, SH, Sloan, JA, Kutteh, L, Fitch, TR, et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 81:6 (2006), 758–767.
55. Balci Akpinar, R, Celebioglu, A, Effect of injection duration on bruising associated with subcutaneous heparin: a quasi-experimental within-subject design. Int J Nurs Stud 45:6 (2008), 812–817.
56. Chan, H, Effects of injection duration on site-pain intensity and bruising associated with subcutaneous heparin. J Adv Nurs 35:6 (2001), 882–892.
57. Zaybak, A, Khorshid, L, A study on the effect of the duration of subcutaneous heparin injection on bruising and pain. J Clin Nurs 17:3 (2008), 378–385.
58. Kuzu, N, Ucar, H, The effect of cold on the occurrence of bruising, haematoma and pain at the injection site in subcutaneous low molecular weight heparin. Int J Nurs Stud 38:1 (2001), 51–59.
59. Ross, S, Soltes, D, Heparin and haematoma: does ice make a difference?. J Adv Nurs 21:3 (1995), 434–439.
60. Ihnat, DM, Mills, JL, Hughes, JD, Gentile, AT, Berman, SS, Westerband, A, Treatment of patients with venous thromboembolism and malignant disease: should vena cava filter placement be routine?. J Vasc Surg 28:5 (1998), 800–807.
61. Opatrny, L, Warner, MN, Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am J Hematol 76:3 (2004), 240–244.
62. Prandoni, P, Falanga, A, Piccioli, A, Cancer, thrombosis and heparin-induced thrombocytopenia. Thromb Res 120:Suppl 2 (2007), S137–S140.
63. Warkentin, TE, Heparin-induced thrombocytopenia: diagnosis and management. Circulation 110:18 (2004), e454–e458.
64. Klerk, CP, Smorenburg, SM, Otten, HM, Lensing, AW, Prins, MH, Piovella, F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23:10 (2005), 2130–2135.
65. Noble, SI, Finlay, IG, Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med 19:3 (2005), 197–201.
66. Noble, SI, Nelson, A, Turner, C, Finlay, IG, Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. BMJ 332:7541 (2006), 577–580.
67. Dranitsaris, G, Vincent, M, Crowther, M, Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis. Pharmacoeconomics 24:6 (2006), 593–607.
68. Laupacis, A, Feeny, D, Detsky, AS, Tugwell, PX, How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146:4 (1992), 473–481.
69. Marchetti, M, Pistorio, A, Barone, M, Serafini, S, Barosi, G, Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Med 111:2 (2001), 130–139.
70. Kryworuchko, J, Stacey, D, Bai, N, Graham, ID, Twelve years of clinical practice guideline development, dissemination and evaluation in Canada (1994 to 2005). Implement Sci, 4, 2009, 49.